Arcus Biosciences (RCUS) Receivables (2017 - 2025)

Arcus Biosciences' Receivables history runs 9 years deep, the most recent figure standing at $18.0 million for Q1 2025.

• On a quarterly basis, Receivables fell 93.16% year-over-year to $18.0 million in Q1 2025; TTM through Mar 2025 was $18.0 million, a 93.16% decrease from a year earlier, with the FY2024 full-year figure at $248.0 million, up 504.88% from the prior year.
• Receivables declined to $18.0 million in Q1 2025 per RCUS's latest filing, from $248.0 million in the prior quarter.
• Across five years, Receivables topped out at $749.9 million in Q4 2021 and bottomed at $4.8 million in Q3 2021.
• The 5-year median for Receivables is $40.2 million (2022), against an average of $124.4 million.
• Across the five-year window, Receivables jumped 14480.98% in 2021 and slumped 94.27% in 2022, its largest moves.
• Year by year, Receivables stood at $749.9 million in 2021, then slumped by 94.27% to $43.0 million in 2022, then dropped by 4.65% to $41.0 million in 2023, then surged by 504.88% to $248.0 million in 2024, then sank by 92.74% to $18.0 million in 2025.
• Per Business Quant, the three latest RCUS Receivables figures stand at $18.0 million (Q1 2025), $248.0 million (Q4 2024), and $244.0 million (Q3 2024).